tiprankstipranks
Trending News
More News >
Takeda Pharmaceutical Co Ltd (JP:4502)
:4502

Takeda Pharmaceutical Co (4502) Price & Analysis

Compare
5 Followers

4502 Stock Chart & Stats


Bulls Say, Bears Say

Bulls Say
Clinical TrialsRusfertide achieved the primary endpoint as well as all key secondary endpoints in the Ph3 study.
Market PotentialTakeda disclosed projections that rusfertide peak sales could reach $1-2bn, indicating strong market potential.
Bears Say
Patent ExpiryVyvanse going off patent will have long-term effects, impacting the company's performance.
Regulatory ChallengesThe US’s 340B program and Medicare Part D redesign are estimated to have a significant financial impact on Takeda, totaling JPY130Bn for FY2025.

Financials

Options Prices

Currently, No data available
---

Ownership Overview

7.05%<0.01%82.74%
7.05%
Mutual Funds
<0.01% Other Institutional Investors
82.74% Public Companies and
Individual Investors

4502 FAQ

What was Takeda Pharmaceutical Co Ltd’s price range in the past 12 months?
Takeda Pharmaceutical Co Ltd lowest stock price was ¥3852.00 and its highest was ¥4573.00 in the past 12 months.
    What is Takeda Pharmaceutical Co Ltd’s market cap?
    Takeda Pharmaceutical Co Ltd’s market cap is $6.89T.
      When is Takeda Pharmaceutical Co Ltd’s upcoming earnings report date?
      Takeda Pharmaceutical Co Ltd’s upcoming earnings report date is Jul 30, 2025 which is in 44 days.
        How were Takeda Pharmaceutical Co Ltd’s earnings last quarter?
        Takeda Pharmaceutical Co Ltd released its earnings results on May 08, 2025. The company reported -¥66 earnings per share for the quarter, missing the consensus estimate of -¥8.84 by -¥57.16.
          Is Takeda Pharmaceutical Co Ltd overvalued?
          According to Wall Street analysts Takeda Pharmaceutical Co Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Takeda Pharmaceutical Co Ltd pay dividends?
            Takeda Pharmaceutical Co Ltd pays a Annually dividend of ¥98 which represents an annual dividend yield of 4.43%. See more information on Takeda Pharmaceutical Co Ltd dividends here
              What is Takeda Pharmaceutical Co Ltd’s EPS estimate?
              Takeda Pharmaceutical Co Ltd’s EPS estimate is 51.04.
                How many shares outstanding does Takeda Pharmaceutical Co Ltd have?
                Takeda Pharmaceutical Co Ltd has 1,590,961,700 shares outstanding.
                  What happened to Takeda Pharmaceutical Co Ltd’s price movement after its last earnings report?
                  Takeda Pharmaceutical Co Ltd reported an EPS of -¥66 in its last earnings report, missing expectations of -¥8.84. Following the earnings report the stock price went down -0.834%.
                    Which hedge fund is a major shareholder of Takeda Pharmaceutical Co Ltd?
                    Currently, no hedge funds are holding shares in JP:4502

                    Company Description

                    Takeda Pharmaceutical Co Ltd

                    Takeda Pharmaceutical Co., Ltd. is a leading global biopharmaceutical company, headquartered in Japan, focusing on delivering life-transforming treatments. The company operates in a variety of therapeutic areas, including oncology, gastroenterology, neuroscience, rare diseases, plasma-derived therapies, and vaccines. Takeda is committed to innovation and research, utilizing its extensive R&D capabilities to develop therapies that address unmet medical needs and enhance patients' quality of life.

                    4502 Company Deck

                    4502 Earnings Call

                    Q4 2025
                    0:00 / 0:00
                    Earnings Call Sentiment|Neutral
                    Takeda demonstrated strong performance and growth in its product portfolio and pipeline, with positive financial results and shareholder returns. However, challenges from VYVANSE's loss of exclusivity, ENTYVIO's U.S. market issues, and higher taxes slightly dampened the overall results.Read More>

                    4502 Stock 12 Month Forecast

                    Average Price Target

                    ¥5,038.65
                    ▲(15.86%Upside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2680":"¥2,680","3376":"¥3,376","4072":"¥4,072","4768":"¥4,768","5464":"¥5,464"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5463.7847124124,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥5.46K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5038.648726144,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥5.04K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4470.3693101556,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥4.47K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2680,3376,4072,4768,5464],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4276,4367.368054800954,4458.736109601908,4550.104164402862,4641.472219203815,4732.8402740047695,4824.208328805723,4915.576383606677,5006.9444384076305,5098.312493208585,5189.680548009538,5281.048602810492,5372.416657611446,{"y":5463.7847124124,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4276,4334.665286626461,4393.330573252923,4451.995859879385,4510.661146505846,4569.326433132308,4627.991719758769,4686.6570063852305,4745.322293011692,4803.987579638154,4862.652866264615,4921.318152891076,4979.9834395175385,{"y":5038.648726144,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4276,4290.951485396585,4305.9029707931695,4320.854456189754,4335.805941586338,4350.757426982923,4365.708912379508,4380.660397776092,4395.611883172677,4410.563368569262,4425.514853965846,4440.4663393624305,4455.417824759015,{"y":4470.3693101556,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2779.388,"date":1635724800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2681.101,"date":1640995200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3989.164,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4007.327,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3997.768,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4058.971,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4030.594,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4091.263,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4118.662,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4240.979,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4509,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4372,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4276,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Sumitomo Dainippon Pharma Co
                    Tsumura & Co
                    Hisamitsu Pharmaceutical Co
                    Shionogi & Co
                    Eisai Co
                    Popular Stocks
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis